Design and Synthesis of 4-Arylazo Pyrazole Carboxamides as Dual AChE/BChE Inhibitors: Kinetic and In Silico Evaluation
Pharmaceuticals · 29.01.2026 · 19 (2) · 239
DOI: 10.3390/ph19020239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 29.01.2026. Verfasst von Suleyman Akocak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Adıyaman University, Adıyaman 02040, Türkiye. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Research Fund of Adıyaman, Research Fund of Adıyaman University.
Abstract (Originalsprache)
Background/Objectives: Pyrazole carboxamides are widely used as adaptable medicinal-chemistry scaffolds and have been explored as cholinesterase (ChE) inhibitor chemotypes. In this work, we prepared a new series of 4-arylazo-3,5-diamino-N-tosyl-1H-pyrazole-1-carboxamides 5(a–m) and evaluated their inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), supported by structure-based computational analyses.
Methods
Thirteen derivatives 5(a–m) were synthesized, fully characterized with analytical techniques (FT-IR, H NMR, and C NMR), and tested in vitro against AChE and BChE, with tacrine (THA) used as the reference inhibitor. Docking calculations were used to examine plausible binding modes. The top-ranked complexes (7XN1–5e and 4BDS–5i) were further examined by 100 ns explicit-solvent molecular dynamics (MD) simulations in Cresset Flare, followed by RMSD/RMSF analysis and contact-persistence profiling. Predicted ADME/Tox. properties were also assessed to identify potential developability issues.
Results
The series showed strong ChE inhibition, and several compounds were more potent than THA. Compound 5e (4-nitro) was the most active AChE inhibitor (KI = 20.86 ± 1.61 nM) compared with THA (KI = 164.40 ± 20.84 nM). For BChE, the KI values ranged from 31.21 to 87.07 nM and exceeded the reference compound’s activity. MD trajectories supported stable binding in both systems (10–100 ns mean backbone RMSD: 2.21 ± 0.17 Å for 7XN1–5e; 1.89 ± 0.11 Å for 4BDS–5i). Most fluctuations were confined to flexible regions, while key contacts remained in place, consistent with the docking models. ADME/Tox. predictions suggested moderate lipophilicity but generally low aqueous solubility; all compounds were predicted as non-BBB permeant, and selected liabilities were flagged (e.g., carcinogenicity for 5e/5g/5h/5i; nephrotoxicity for 5f/5g).
Conclusions
The 4-arylazo-3,5-diamino-N-tosyl-1H-pyrazole-1-carboxamide scaffold delivers low-nanomolar ChE inhibition, with docking and MD supporting stable binding modes. Future optimization should prioritize solubility improvement and mitigation of predicted toxicities and metabolic liabilities, especially given the predicted lack of BBB permeability for CNS-directed applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Adıyaman University, Adıyaman 02040, Türkiye.
- Department of Medical Biochemistry, Faculty of Medicine, Kafkas University, Kars 36100, Türkiye.
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan 24002, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.
- Institute of Biological and Chemical Systems Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology (KIT), Kaiserstrasse 12, 76131 Karlsruhe, Germany.
- Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan 24002, Türkiye.
ORCID-Profile: Suleyman Akocak, Hatice Esra Duran, Büşra Demir Çetinkaya, Hamada Hashem, Stefan Bräse, Cüneyt Türkeş
Förderung
- the Research Fund of Adıyaman
- Research Fund of Adıyaman University
Zitieren
APA
Akocak, S., Lolak, N., Duran, H. E., Demir Çetinkaya, B., Hashem, H., Bräse, S., & Türkeş, C. (2026). Design and Synthesis of 4-Arylazo Pyrazole Carboxamides as Dual AChE/BChE Inhibitors: Kinetic and In Silico Evaluation. Pharmaceuticals, 19(2), 239. https://doi.org/10.3390/ph19020239
Vancouver
Akocak S, Lolak N, Duran HE, Demir Çetinkaya B, Hashem H, Bräse S, et al. Design and Synthesis of 4-Arylazo Pyrazole Carboxamides as Dual AChE/BChE Inhibitors: Kinetic and In Silico Evaluation. Pharmaceuticals. 2026;19(2):239. doi:10.3390/ph19020239
BibTeX
@article{Akocak2026,
author = {Akocak, Suleyman and Lolak, Nebih and Duran, Hatice Esra and Demir Çetinkaya, Büşra and Hashem, Hamada and Bräse, Stefan and Türkeş, Cüneyt},
title = {Design and Synthesis of 4-Arylazo Pyrazole Carboxamides as Dual AChE/BChE Inhibitors: Kinetic and In Silico Evaluation},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {2},
pages = {239},
doi = {10.3390/ph19020239}
}
EUVIMED